All News
EULAR 2017 – Day 4 Highlights
Saturday was a day of big posters and special seminars at EULAR in Madrid. In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session.
Read ArticleConcomitant Septic Arthritis and Crystalline Arthropathy
Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.
Read Article
EULAR 2017 – Day 3 Highlights
Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.
Here are the major presentations from several clinical areas.
Read ArticleHerpes Zoster
Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ).
Read Article
Lancet Launches EULAR 2017 and "A Platinum Age of Rheumatology"
The current Lancet edition for 10 June 2017 is a rheumatology rich collection.
Read Article
Supreme Court Decision Favors Earlier Biosimilar Adoption
On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.
Read Article
FDA Approves Abatacept for Pediatric Use
Subcutaneous (SC) abatacept (Orencia) is now available for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic (JIA) according to Bristol-Myers Squibb.
Read Article
Suspending Methotrexate for Influenza Vaccination
Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity.
Read Article
Debate over Alcohol and Methotrexate Precautions
Drs. Kremer and Weinblatt have responded to a recent Annals of Rheumatic Disease article regarding the hepatic risks of alcohol use with methotrexate (MTX) therapy authored by Humphries et al. (Citation source: http://buff.ly/2r70uuz)
Read Article
2017 ACR Guideline on Glucocorticoid-Induced Osteoporosis
The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.
Read Article
Upadacitinib Effective in Rheumatoid Arthritis
AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in established RA patients who have failed prior DMARD therapy.
Read Article
Nurse-Led Patient Care in Rheumatology
Manpower in rheumatology is about to be a major problem for the next several decades: not enough trainees, a "tsunami of retiring older white rheumatologists", and an aging baby-boomer, arthritis-primed population will strain current resources and manpower. Moreover, necessary services will not likely be available to those in need and there may be a significant maldistribution of adequate rheumatologic care.
Read Article
Biosimilar Reports – May 2017
Biosimilars continue to command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. Biosimilar Reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists.
Read Article
Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women
The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures.
Read Article
Both Undertreatment and Overtreatment Common in JIA
Kimme L. Hyrich, MD, PhD, of the University of Manchester in the United Kingdom, and colleagues point out that because of the lack of consensus in diagnostic criteria, "the same child could be classified as 'in clinically inactive disease' or having active disease at the same time point between clinicians or hospitals."
Read Article
Golimumab Fails in Polyarticular Juvenile Arthritis
Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis.
Read Article
Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis
Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.
Read Article
High Fiber Intake May Decrease Osteoarthritis Knee Pain
Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)
Read Article
The RheumNow Week in Review - 26 May 2017
Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:
Read Article
IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis
The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).
Read Article